Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Boehringer Ingelheim | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Boehringer Ingelheim

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim

1H Revenues: $9.2 billion (+3%)

Comments: Pharmaceutical sales were $6.9 billion (+4%) in the first half, driven by Pradaxa (+28%), newly launched Trajenta, and Spiriva (+4%). OTC medicines grew by an adjusted 8% to $926.1 million. Biopharmaceuticals sales were down 21% to $218.5 million as a result of third party supply contracts ending in the reporting period.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters